Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy
Cancer Drug Resistance,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 25, 2024
Competing
endogenous
RNAs
(ceRNAs)
are
transcripts
that
possess
highly
similar
microRNA
response
elements
(MREs).
microRNAs
(miRNAs)
short,
endogenous,
single-stranded
non-coding
(ncRNAs)
can
repress
gene
expression
by
binding
to
MREs
on
the
3’
untranslated
regions
(UTRs)
of
target
mRNA
suppress
promoting
degradation
and/or
inhibiting
protein
translation.
transcripts,
circular
(circRNAs),
long
(lncRNAs),
and
transcribed
pseudogenes
could
share
MREs,
they
compete
for
same
pool
miRNAs.
These
ceRNAs
may
affect
level
one
another
competing
their
shared
This
interplay
between
different
constitutes
a
ceRNA
network,
which
regulates
many
important
biological
processes.
Cancer
drug
resistance
is
major
factor
leading
treatment
failure
in
patients
receiving
chemotherapy.
It
be
acquired
through
genetic,
epigenetic,
various
tumor
microenvironment
mechanisms.
The
involvement
crosstalk
its
disruption
chemotherapy
attracting
attention
cancer
research
community.
review
presents
an
updated
summary
latest
dysregulation
causing
across
types
chemotherapeutic
classes.
Interestingly,
accumulating
evidence
suggests
used
as
prognostic
biomarkers
predict
clinical
Nevertheless,
detailed
experimental
investigations
putative
networks
generated
computational
algorithms
needed
support
translation
therapeutic
applications.
Язык: Английский
Upregulated lncRNA LINC01128 in colorectal cancer accelerates cell growth and predicts malignant prognosis through sponging miR-363-3p
Journal of Cancer Research and Clinical Oncology,
Год журнала:
2024,
Номер
150(5)
Опубликована: Май 26, 2024
Colorectal
cancer
(CRC)
refers
to
high-mortality
tumors
arising
in
the
colon
or
rectum
with
a
high
rate
of
recurrence.
The
involvement
long
non-coding
RNAs
(lncRNAs)
contributes
treatment
and
prognosis
evaluation
CRC,
brings
new
direction
for
radical
cure
patients.
To
identify
pathological
mechanism
regulation
lncRNA
LINC01128
(LINC01128)
on
CRC
cells,
analyze
its
potential
prognostic
value.
Язык: Английский
Circular RNAs: key players in tumor immune evasion
Molecular and Cellular Biochemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 4, 2025
Язык: Английский
Circular RNAs modulate cancer drug resistance: advances and challenges
Cancer Drug Resistance,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 28, 2025
Acquired
drug
resistance
is
a
main
factor
contributing
to
cancer
therapy
failure
and
high
mortality,
highlighting
the
necessity
develop
novel
intervention
targets.
Circular
RNAs
(circRNAs),
an
abundant
class
of
RNA
molecules
with
closed
loop
structure,
possess
characteristics
including
stability,
which
provide
unique
advantages
in
clinical
application.
Growing
evidence
indicates
that
aberrantly
expressed
circRNAs
are
associated
against
various
treatments,
targeted
therapy,
chemotherapy,
radiotherapy,
immunotherapy.
Therefore,
targeting
these
aberrant
may
offer
strategy
improve
efficiency
therapy.
Herein,
we
present
summary
most
recently
studied
their
regulatory
roles
on
resistance.
With
advances
artificial
intelligence
(AI)-based
bioinformatics
algorithms,
could
emerge
as
promising
biomarkers
targets
Язык: Английский
Expression Profile of Serum CircFUNDC1 and CircUHRF1 Can Differentiate Between Colorectal Cancer and Inflammatory Bowel Diseases (Ulcerative Colitis and Crohn's Disease)
Journal of Clinical Laboratory Analysis,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 16, 2025
ABSTRACT
Background
Colorectal
cancer
(
CRC
)
is
a
worldwide
burden.
Circular
RNAs
are
promising
biomarkers
for
diagnosing
and
prognosis
of
.
Objective
To
investigate
the
possible
association
sera
levels
CircFUNDC1
CircUHRF1
expression
with
predisposition
clinicopathological
findings
in
,
ulcerative
colitis
UC
),
Crohn's
disease
CD
Egyptian
patients.
Methods
The
serum
were
evaluated
113
subjects
divided
into
four
groups;
(31),
(26),
(25)
compared
to
healthy
controls
(31)
using
quantitative
polymerase
chain
reaction.
Results
median
values
log2
fold
change
FC
patients
9.11,
6.58,
6.17,
respectively.
It
was
upregulated
all
case
groups.
had
significantly
higher
than
p
<
0.001).
However,
there
no
significant
differences
among
patient
groups
).
medians
log
2
−2.00,
3.33,
3.12,
level
lower
group
patients,
difference
between
controls.
Serum
overexpressed
or
By
Roc
curve
analysis,
both
genes
can
differentiate
from
inflammatory
bowel
IBD
0.05.
Conclusion
biomarker
while
Язык: Английский
LINC00513 promotes colorectal cancer malignant progression by binding with IGF2BP1 to enhance the stability of connective tissue growth factor mRNA
Epigenomics,
Год журнала:
2024,
Номер
16(14), С. 985 - 998
Опубликована: Июль 17, 2024
Aim:
This
study
aimed
to
investigate
the
role
of
LINC00513
in
colorectal
cancer
(CRC)
progression.
Materials
&
methods:
Cell
proliferation
was
evaluated
using
Counting
Kit-8.
migration
detected
with
transwell
assay.
RNA
pull-down
applied
for
verifying
interactions
between
LINC00513,
IGF2BP1
and
connective
tissue
growth
factor
(CTGF).
Results:
CTGF
levels
were
upregulated
CRC.
Knockdown
significantly
inhibited
malignant
behavior
CRC
cells.
increased
mRNA
stability
by
binding
IGF2BP1.
Furthermore,
overexpression
or
reversed
inhibitory
effect
shRNA
on
Conclusion:
promoted
cell
behaviors
through
IGF2BP1/CTGF.
Язык: Английский